Tryptamines are a diverse group of 5HT2A agonist compounds. The predominant clinical effect produced by tryptamine exposure is hallucinations, mediated by agonism at 5HT2A and 5HT1A receptors.

Tryptamines are metabolised by a number of pathways including monoamine oxidase, limiting the oral bioavailability of some compounds.

Showing all 14 results